<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et disease (BD) were treated with oral <z:chebi fb="0" ids="49662">indomethacin</z:chebi> 25 mg four times daily for 3 months as an open label study </plain></SENT>
<SENT sid="1" pm="."><plain>The study population consisted of 13 women and 17 men from 15 to 45 years of age (mean 27 years) </plain></SENT>
<SENT sid="2" pm="."><plain>At the initiation of the therapy, 28 patients had oral aphthous lesions, 23 had joint involvement, 13 had <z:e sem="disease" ids="C0151281" disease_type="Disease or Syndrome" abbrv="">genital ulcerations</z:e>, 8 had cutaneous lesions, and 4 had eye involvement </plain></SENT>
<SENT sid="3" pm="."><plain>Eighty-eight percent of patients with <z:mp ids='MP_0001212'>skin lesions</z:mp>, 80% with joint involvement, 43% with oral aphthous lesions, and 38% with <z:e sem="disease" ids="C0151281" disease_type="Disease or Syndrome" abbrv="">genital ulcerations</z:e> responded to <z:chebi fb="0" ids="49662">indomethacin</z:chebi> therapy </plain></SENT>
<SENT sid="4" pm="."><plain>In three patients <z:chebi fb="0" ids="49662">indomethacin</z:chebi> was changed to the suppository form due to gastrointestinal side effects </plain></SENT>
<SENT sid="5" pm="."><plain>Although it is difficult to assess the efficacy of <z:chebi fb="0" ids="49662">indomethacin</z:chebi> in BD because of the intermittent nature of symptoms, the majority of patients showed improvement in their symptoms of <z:hpo ids='HP_0001369'>arthritis</z:hpo> and <z:mp ids='MP_0001212'>skin lesions</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>This study indicates that <z:chebi fb="0" ids="49662">indomethacin</z:chebi> can be used as effective therapy particularly in patients with joint involvement </plain></SENT>
</text></document>